Core Viewpoint - The Hong Kong innovative drug sector has shown signs of recovery after a period of decline, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising by 1.09% on December 4, ending a four-day losing streak and indicating a significant rebound in market sentiment [1][8]. Market Performance - The Hong Kong innovative drug sector has been in a phase of adjustment since early September, with the Hong Kong Stock Connect Innovative Drug ETF (520880) index experiencing a decline of nearly 16% from its previous high, suggesting that prior high-risk levels have been adequately released [3][11]. - The ETF's trading volume reached 248 million yuan, reflecting increased market activity and interest in the sector [1][8]. Positive News Factors - Two major positive developments have been reported: the launch of the Chinese drug price registration system on December 2, which provides market price references for drug imports and exports, and the anticipated release of the new basic medical insurance drug list and the first commercial insurance innovative drug list by the end of the week, which could optimize the payment structure for innovative drug companies [3][11]. Investment Outlook - Short-term forecasts from CITIC Securities suggest that innovative drugs are expected to be a primary upward trend in the market heading into 2026, supported by a robust domestic demand base and comprehensive manufacturing capabilities within the pharmaceutical industry [5][13]. - The current market conditions may present a favorable opportunity for medium to long-term investments in core innovative drug assets, as the sector is entering a critical phase of "innovation realization and global layout" [5][11]. ETF Characteristics - The Hong Kong Stock Connect Innovative Drug ETF (520880) is noted for its significant concentration in leading stocks, with the top ten holdings accounting for 72.57% of the index, indicating a strong representation of core innovative drug companies [6][14]. - The ETF is characterized by its focus on pure innovative drug companies, excluding CXO firms, and aims to provide comprehensive coverage of the innovative drug development sector [5][13].

Group 1 - The core point of the article is that China Biologic Products (01177.HK) has received approval from the NMPA and FDA for its innovative oral GLP-1 receptor agonist TQF3250, aimed at weight loss [1] - TQF3250 is a small molecule oral GLP-1 receptor agonist that selectively activates the cAMP pathway, promoting insulin secretion while reducing gastrointestinal side effects compared to traditional GLP-1 drugs [1] - The oral administration of TQF3250 enhances patient convenience and long-term treatment adherence compared to injectable GLP-1 medications [1] Group 2 - Obesity and overweight are significant public health challenges, with global adult obesity rates expected to rise from 36% in 2000 to 50% by 2030, affecting nearly 3 billion people [2] - In China, the trend is particularly pronounced, with an estimated 41% of adults projected to have a high BMI (≥25 kg/m²) by 2025, and 9% classified as obese (BMI ≥30 kg/m²) [2] - TQF3250 has also received NMPA approval for clinical trials targeting type 2 diabetes, aligning with the company's focus on metabolic diseases and diverse product pipeline [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） 網站：www.sinobiopharm.com （股份編號：1177） 1 除減重適應症外，TQF3250用於治療2型糖尿病的臨床試驗申請已獲NMPA批准。代謝性疾病是本集 團聚焦的核心治療領域之一，本集團將通過多元化的產品管線，為患者提供更豐富的治療選擇。 參考文獻： 自願公告 TQF3250「口服偏向型GLP-1受體激動劑」臨床試驗申請獲NMPA、FDA批准 中國生物製藥有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」）宣佈，本集團自 主研發的創新藥TQF3250膠囊「口服偏向型GLP-1受體激動劑」的臨床試驗申請已獲得中國國家藥品監 督管理局(NMPA)和美國食品藥品監督管理局(FDA)的批准，擬用於減重。 TQF3250是一款口服小分子偏向型GLP-1受體激動劑。與傳統GLP-1藥物相比，TQF3250通過選擇性 激活cAMP偏向的GLP- ...

Group 1: Market Performance - The Hong Kong Innovation Drug ETF (159570) rebounded by 1.5% after four consecutive declines, with trading volume exceeding 1.2 billion [1] - The ETF has seen a net inflow of over 180 million in the past five days, with a total size exceeding 23.2 billion as of December 3 [1] - Major stocks within the ETF, such as Kangfang Biotech and Kintor Pharmaceutical, experienced gains of over 3% [3] Group 2: Regulatory Developments - On December 3, Xinlitai received approval from the drug regulatory authority to conduct clinical trials for its innovative small molecule drug SAL0140 for chronic kidney disease [3] Group 3: Policy Environment - A significant policy shift is expected in 2025, with the introduction of a commercial insurance innovation drug directory aimed at expanding coverage beyond basic medical insurance [5] - The overall policy direction encourages innovation and aims to alleviate payment pressures, which is expected to positively impact industry sentiment and fundamentals [5] Group 4: Financial Outlook - Leading innovative drug companies are projected to achieve breakeven within the next two years, enhancing market confidence in their profitability [8] - The financial performance of the covered biotech companies indicates a sustained recovery in the pharmaceutical sector [8] Group 5: Investment Trends - The overseas investment environment for innovative drugs remains strong, with record-high transaction numbers and amounts in 2025 [11] - By the end of Q3 2025, 103 outbound transactions were completed, totaling over 92 billion, surpassing the total for 2024 by 77% [11] Group 6: Capital Flow - Both domestic and foreign investments in the Hong Kong pharmaceutical sector have increased, with domestic holdings at 22.1% and foreign holdings at 38.1% as of November 10 [12] - The pharmaceutical sector is expected to attract more capital due to its valuation being below historical averages [12]

Group 1 - The Hang Seng Healthcare Index (HSHCI) has risen by 1.17% as of December 4, 2025, with notable increases in stocks such as InnoCare Pharma (up 4.91%), CanSino Biologics (up 4.65%), and MicroPort Scientific (up 4.51%) [1] - The 11th batch of national centralized procurement results was released on November 7, including 453 products across 55 varieties, with an average price reduction of approximately 75% compared to the highest valid bid [1] - The upcoming ESMO Asia 2025 conference will take place from December 5-7, and the 67th American Society of Hematology (ASH) meeting will be held from December 6-9, which are expected to catalyze data releases in the healthcare sector [1] Group 2 - The top ten weighted stocks in the Hang Seng Healthcare Index (HSHCI) account for 60.48% of the index, including companies like BeiGene, Innovent Biologics, and WuXi Biologics [2] - The Hang Seng Healthcare ETF (159557) closely tracks the HSHCI, providing a market reference for the performance of healthcare securities listed in Hong Kong [2] - Investors without stock accounts can access the Hong Kong healthcare sector investment opportunities through the Hang Seng Healthcare ETF linked fund (018433) [2]

Market Overview - The Hang Seng Index fell to 25,761 points, down 1.3%, while the Hang Seng China Enterprises Index dropped 1.7% to 9,029 points[1] - Total turnover in Hong Kong stocks was HKD 164.4 billion, a decrease of 7.7% from HKD 178.2 billion on Tuesday, indicating a lack of investor confidence[1] - The materials and conglomerates indices rose by 1.2% and 0.1%, respectively, while healthcare, consumer discretionary, and real estate sectors declined by 1.8%, 1.5%, and 1.4%[1] Stock Performance - Techtronic Industries (669 HK) and China Hongqiao (1378 HK) led the gainers, rising by 3.2% and 2.3% respectively[1] - China Life (2628 HK) and China Resources Land (1109 HK) were the biggest losers, falling by 3.6% and 3.1% respectively[1] Industry Dynamics - In the copper market, Chinese smelters oppose negative processing fees from Chilean miners, potentially impacting global refined copper supply and prices[2] - The automotive sector faced pressure, with major players like BYD (1211 HK) and Geely (175 HK) declining by 1.5% to 2%[4] - The pharmaceutical sector showed weakness, with outpatient growth slowing from 9.8% to 0.8% year-on-year, indicating a challenging operating environment[5] Economic Indicators - China's November services PMI was reported at 52.1, slightly above expectations but down from October's 52.6[3] - The U.S. private sector saw a decrease of 32,000 jobs in November, contrasting with an expected increase of 10,000[3] - The ISM services PMI in the U.S. was 52.6, exceeding expectations of 52.1[3]

Group 1 - The core viewpoint of the news is that after a four-day decline, the Hong Kong innovative drug sector has rebounded, with leading stocks like Kangfang Biotech and Rongchang Biotech showing significant gains [1][7] - The Hong Kong Stock Connect Innovative Drug ETF (520880) has over 70% of its holdings in leading innovative drug stocks, indicating strong market confidence [1][7] - The innovative drug sector is expected to be a major upward trend in the cross-year market, supported by China's pharmaceutical industry entering a critical phase of "innovation realization + global layout" [3][9] Group 2 - The Hong Kong Stock Connect Innovative Drug ETF (520880) has a total scale of 2.142 billion yuan and an average daily trading volume of 458 million yuan since its listing, making it the largest and most liquid ETF tracking the same index [5][10] - The index tracked by the ETF, the Hang Seng Stock Connect Innovative Drug Select Index, has a high concentration of leading stocks, with the top ten stocks accounting for 72.57% of the total weight, showcasing the strength of the innovative drug sector [3][10] - The ETF is designed to cover pure innovative drug companies without including CXO, ensuring a comprehensive representation of the innovative drug research and development sector [4][9]

Market Overview - The Hong Kong stock market experienced a decline, with the Hang Seng Index closing at 23,831 points, down 145 points or 0.61% [1] - The market turnover decreased to 82.799 billion HKD, with net inflows of 484 million HKD recorded in the Hong Kong Stock Connect [1][5] - The US stock market saw gains, with the Dow Jones rising by 408.44 points or 0.86%, closing at 47,882.90 points [2] Sector Performance - In Hong Kong, local real estate, software, and 5G concept sectors faced significant declines, while gold stocks performed well [1] - The technology sector in Hong Kong saw a broad retreat, with the Hang Seng Technology Index dropping by 1.58% [1][5] - The copper price reached a historical high due to supply concerns and a weaker dollar, with a year-to-date increase of 31% [9] Investment Opportunities - The report emphasizes the attractiveness of low-valuation, high-dividend sectors in Hong Kong, particularly in technology, artificial intelligence, semiconductors, and industrial software [3] - Companies benefiting from the anticipated US Federal Reserve interest rate cuts and strong mid-term performance in the upstream non-ferrous metals sector are highlighted as potential investment opportunities [3] - The report suggests focusing on leading companies in the AI and technology sectors, which are expected to benefit from self-reliance initiatives [3] Company Highlights - Alibaba's "Qianwen" app has shown significant growth, ranking first in global AI application growth with a monthly active user growth rate of 149.03% [9][12] - China Software International (0354.HK) is noted for its strong positioning in IT services and its collaboration with Huawei, with projected revenue of 16.951 billion CNY for 2024 [10] - The report indicates that leading companies in copper mining and smelting, such as China Nonferrous Metal Mining (1258.HK) and Luoyang Molybdenum (3993.HK), are worth monitoring due to the tight supply-demand balance in the copper market [9]

Market Overview - The Hang Seng Index has short-term support at the 25,000 point level, with recent hawkish comments from the Federal Reserve indicating less room for interest rate cuts than previously expected. The meeting between the Chinese and US leaders in October has temporarily eased tensions, but core issues remain unresolved. The economic slowdown in mainland China continues, and corporate earnings in Hong Kong are unlikely to improve significantly in the short term. The recent volatility in US tech stocks and the large cumulative gains in Hong Kong stocks this year may lead to profit-taking by year-end [2][5][7]. Macro Focus - China's November RatingDog services PMI fell to 52.1, the lowest in five months, indicating a slowdown in service sector growth. The government is focusing on urban renewal and stabilizing the real estate market as part of its 14th Five-Year Plan. The US Congress has reportedly halted restrictions on chip sales to China, while the Trump administration is considering policies to promote AI and robotics development. Additionally, the US ADP report showed a surprising decrease of 32,000 private sector jobs in November, falling short of expectations [3][10][11]. Company News - Meituan has been reduced by Prosus, resulting in a cash-out of HKD 4.2 billion, with the CEO stating that the sale was due to underperforming investments. AAC Technologies is a key supplier for Alibaba's Quark AI glasses and Doubao AI phone. Li Auto has launched its Livis AI glasses starting at RMB 1,999 [4][12]. Sector Outlook - The AI glasses and smartphone sector is gaining attention with the launch of Quark AI glasses and Doubao AI phone, benefiting from the supply chain. The biopharmaceutical sector is also expected to perform well due to the rising flu season and favorable interest rate cuts for global biotech financing. The insurance sector is seeing improved investment returns driven by strong A-share performance [8][10]. Stock Market Performance - The Hang Seng Index closed at 25,761, down 1.28% year-to-date, with the Hang Seng Tech Index down 1.58% but up 23.88% year-to-date. The Shanghai Composite Index fell 0.51% but is up 15.70% year-to-date. The US stock market showed positive movement with a slight increase in major indices following the ADP employment report [6][7]. New Listings - Several companies are preparing for IPOs, including Hansi Aitai Biotech, which focuses on cancer immunotherapy, and Nobi AI Technology, which specializes in AI and digital twin applications. Guoxia Technology is also set to list, providing renewable energy solutions in the energy storage sector [12].

Group 1: Company Announcements - JD Industrial (07618) plans to globally issue 211 million shares, with an expected listing date of December 11 [1] - China Gas (00384) adheres to its "green city operator" strategy, building a multi-energy complementary energy system and ecological collaboration, signing a strategic cooperation agreement with EVE Energy [1] - China Nuclear International (02302) indirectly controlled parent company China Uranium Industry officially listed on the Shenzhen Stock Exchange, highlighting its enhanced capital market position [1] - Innoscience (02577) and ON Semiconductor have reached a strategic cooperation agreement to accelerate the development of the gallium nitride industry ecosystem [1] - Innoscience (02577) won a lawsuit against Infineon, with the ITC ruling that the two involved patents were not infringed [1] - Wangshan Wangshui-B (02630) and Ascletis Pharma (02096) signed a licensing agreement for the new indication of VV116 [1] - China Biopharmaceutical (01177) received approval for the launch of the Rotigotine patch [1] - Dechra Pharmaceuticals-B (06996) received approval in Hong Kong for the use of Hivio® in treating multiple myeloma and diffuse large B-cell lymphoma [1] - Xianruida Medical-B (06669) received approval from the National Medical Products Administration for the registration application of the microcatheter V-otter [1] - Jiajie Ankang-B (02617) had its Tiengogatin tablets approved for inclusion in the priority review list by the National Medical Products Administration [1] - Yuexiu Transportation Infrastructure (01052) plans to acquire 85% equity of Shandong Qinbin Expressway for 1.1535 billion yuan [1] Group 2: Share Buybacks and Holdings - Tencent Holdings (00700) repurchased 1.04 million shares for 636 million HKD on December 3 [2] - Xiaomi Group-W (01810) spent approximately 302 million HKD to repurchase 7.5 million shares on December 3 [2] - Midea Group (00300) repurchased 121.27 million A-shares for 99.9984 million yuan on December 3 [2] - SF Express (06936) repurchased 163.86 million A-shares for 62.1907 million yuan on December 3 [2] - COSCO Shipping Holdings (01919) repurchased 3 million shares for 41.3725 million HKD on December 3 [2] - China Feihe (06186) repurchased 400,000 shares for 16.7927 million HKD on December 3 [2] - Galen Pharmaceuticals-B (01672) repurchased 130.6 million shares for 15.9275 million HKD on December 3 [2] - Fenbi (02469) repurchased 453.05 million shares for 14.359 million HKD on December 3 [2] - Jieli Trading Treasure (08017) saw Chairman and Executive Director Liu Yong increase holdings by 1 million shares [2] - Yiming Anke-B (01541) had Executive Director Tian Wenzhi increase holdings by 50,000 H-shares [2] - Dongfang Electric (01072) announced that Senior Vice President Wang Jun plans to reduce holdings by no more than 6,250 shares [2] - Red Star Macalline (01528) shareholder Hangzhou Haoyue plans to reduce holdings by no more than approximately 131 million shares [2] Group 3: Operating Performance - Agile Group (03383) reported a total pre-sale amount of approximately 8.08 billion yuan in the first 11 months, a year-on-year decrease of 45.2% [2]